Suppr超能文献

在辅助性癌症治疗决策中使用隐性说服:共同决策的潜在障碍。

Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making.

作者信息

Engelhardt Ellen G, Pieterse Arwen H, van der Hout Anja, de Haes Hanneke J C J M, Kroep Judith R, Quarles van Ufford-Mannesse Patricia, Portielje Johanneke E A, Smets Ellen M A, Stiggelbout Anne M

机构信息

Department of Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands.

Department of Medical Psychology, Academic Medical Center, Amsterdam, The Netherlands.

出版信息

Eur J Cancer. 2016 Oct;66:55-66. doi: 10.1016/j.ejca.2016.07.011. Epub 2016 Aug 15.

Abstract

BACKGROUND

Shared decision making (SDM) is widely advocated, especially for preference-sensitive decisions like those on adjuvant treatment for early-stage cancer. Here, decision making involves a subjective trade-off between benefits and side-effects, and therefore, patients' informed preferences should be taken into account. If clinicians consciously or unconsciously steer patients towards the option they think is in their patients' best interest (i.e. implicit persuasion), they may be unwittingly subverting their own efforts to implement SDM. We assessed the frequency of use of implicit persuasion during consultations and whether the use of implicit persuasion was associated with expected treatment benefit and/or decision making.

METHODS

Observational study design in which consecutive consultations about adjuvant systemic therapy with stage I-II breast cancer patients treated at oncology outpatient clinics of general teaching hospitals and university medical centres were audiotaped, transcribed and coded by two researchers independently.

RESULTS

In total, 105 patients (median age = 59; range: 35-87 years) were included. A median of five (range: 2-10) implicitly persuasive behaviours were employed per consultation. The number of behaviours used did not differ by disease stage (P = 0.07), but did differ by treatment option presented (P = 0.002) and nodal status (P = 0.01). About 50% of patients with stage I or node-negative disease were steered towards undergoing chemotherapy, whereas 96% of patients were steered towards undergoing endocrine therapy, irrespective of expected treatment benefit. Decisions were less often postponed if more implicit persuasion was used (P = 0.03).

INTERPRETATION

Oncologists frequently use implicit persuasion, steering patients towards the treatment option that they think is in their patients' best interest. Expected treatment benefit does not always seem to be the driving force behind implicit persuasion. Awareness of one's use of these steering behaviours during decision making is a first step to help overcome the performance gap between advocating and implementing SDM.

摘要

背景

共同决策(SDM)得到广泛倡导,尤其是对于像早期癌症辅助治疗这类偏好敏感型决策。在此类决策中,需要在获益与副作用之间进行主观权衡,因此应考虑患者的知情偏好。如果临床医生有意或无意地引导患者选择他们认为最符合患者利益的选项(即隐性说服),他们可能在不知不觉中破坏自己实施共同决策的努力。我们评估了会诊期间隐性说服的使用频率,以及隐性说服的使用是否与预期治疗获益和/或决策相关。

方法

采用观察性研究设计,由两名研究人员独立对在综合教学医院和大学医学中心的肿瘤门诊接受治疗的I-II期乳腺癌患者关于辅助全身治疗的连续会诊进行录音、转录和编码。

结果

共纳入105例患者(中位年龄=59岁;范围:35-87岁)。每次会诊中隐性说服行为的中位数为5次(范围:2-10次)。使用的行为数量在疾病分期方面无差异(P=0.07),但在呈现的治疗选项(P=0.002)和淋巴结状态方面存在差异(P=0.01)。约50%的I期或淋巴结阴性疾病患者被引导接受化疗,而96%的患者被引导接受内分泌治疗,无论预期治疗获益如何。如果使用更多的隐性说服,决策较少被推迟(P=0.03)。

解读

肿瘤学家经常使用隐性说服,引导患者选择他们认为最符合患者利益的治疗选项。预期治疗获益似乎并不总是隐性说服背后的驱动力。在决策过程中意识到自己使用这些引导行为是帮助克服倡导和实施共同决策之间的执行差距的第一步。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验